Aptinyx Announces Publication of Review Article Highlighting Preclinical Data in Medicine in Drug Discovery Demonstrating the...
January 19 2021 - 8:31AM
Business Wire
NYX-2925 is currently under evaluation in two
Phase 2b studies of chronic pain: one in patients with fibromyalgia
and a second in patients with painful diabetic peripheral
neuropathy
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical
company developing transformative therapies for the treatment of
brain and nervous system disorders, today announced the publication
of a recent review article in Medicine in Drug Discovery featuring
data on its novel NMDA receptor modulator, NYX-2925. The data span
across numerous preclinical models and highlight the potential
therapeutic benefits of NYX-2925 in treating chronic, centralized
pain conditions.
“This article in Medicine in Drug Discovery showcases our
methodical approach to CNS drug development and also highlights the
important role NYX-2925 could play in treating centralized chronic
pain,” said Norbert Riedel, Ph.D., chief executive officer of
Aptinyx. “We have thoroughly characterized the effects of NYX-2925
across numerous preclinical pain models and have seen robust,
consistent, and reproducible activity that suggests a
differentiated safety and efficacy profile. As we have now advanced
NYX-2925 through two Phase 2 studies and observed clear signals of
activity on several biomarkers as well as patient-reported
measures, these foundational preclinical data continue to be
important to our understanding of the unique mechanism of NMDA
receptor modulation and its role in addressing aberrant central
pain processing. Given all of the compelling evidence we have
gathered to date with NYX-2925, we are eager to complete the two
ongoing Phase 2b studies in the first half of 2022 and to move
closer to our goal of bringing NYX-2925 to patients in need of
better therapeutic options.”
The review describes the role of central (brain) changes that
occur as pain is experienced chronically. These changes can lead to
a maladaptive state that creates a lifelong pain sensation despite
the absence of painful peripheral (sensory) stimuli. Disruptions in
NMDA receptor activity and expression have been implicated in
chronic pain states and this review presents preclinical data from
a variety of preclinical pain models describing the analgesic
effects exhibited by the novel NMDA receptor modulation of
NYX-2925.
About NYX-2925
NYX-2925 is a novel oral NMDA receptor modulator currently in
Phase 2 clinical development for the treatment of chronic pain. In
clinical studies, NYX-2925 has demonstrated activity that affects
central pain processing, resulting in alleviation of pain and other
symptoms associated with chronic pain conditions. In Phase 1 and
Phase 2 clinical studies, NYX-2925 has exhibited a favorable safety
and tolerability profile across a wide dose range. The U.S. Food
and Drug Administration has granted Fast Track designation to
Aptinyx’s development of NYX-2925 for the treatment of neuropathic
pain associated with DPN.
About Aptinyx
Aptinyx Inc. is a clinical-stage biopharmaceutical company
focused on the discovery, development, and commercialization of
proprietary synthetic small molecules for the treatment of brain
and nervous system disorders. Aptinyx has a platform for discovery
of novel compounds that work through a unique mechanism to
modulate—rather than block or over-activate—NMDA receptors and
enhance synaptic plasticity, the foundation of neural cell
communication. The company has three product candidates in clinical
development in central nervous system indications, including
chronic pain, post-traumatic stress disorder, and cognitive
impairment associated with Parkinson’s disease. Aptinyx is also
advancing additional compounds from its proprietary discovery
platform, which continues to generate a rich and diverse pipeline
of small-molecule NMDA receptor modulators with the potential to
treat an array of neurologic disorders. For more information, visit
www.aptinyx.com.
Forward-Looking Statements
Statements contained in this press release regarding matters
that are not historical facts are “forward-looking statements”
within the meaning of the Private Securities Litigation Reform Act
of 1995. Because such statements are subject to risks and
uncertainties, actual results may differ materially from those
expressed or implied by such forward-looking statements. Such
statements include, but are not limited to, statements regarding
the company’s business plans and objectives, including future plans
or expectations for NYX-2925, therapeutic effects of the company’s
product candidates, expectations regarding the design,
implementation, timing, and success of its current and planned
clinical trials, expectations regarding its preclinical development
activities, and expectations regarding its uses and sufficiency of
capital. Risks that contribute to the uncertain nature of the
forward-looking statements include: the success, cost, and timing
of the company’s product candidate development activities and
planned clinical studies; the company’s ability to execute on its
strategy; regulatory developments in the United States and foreign
countries; as well as those risks and uncertainties set forth in
the company’s most recent annual report on Form 10-K and in its
other filings and reports with the United States Securities and
Exchange Commission. All forward-looking statements contained in
this press release speak only as of the date on which they were
made. Aptinyx undertakes no obligation to update such statements to
reflect events that occur or circumstances that exist after the
date on which they were made.
Source: Aptinyx Inc.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210119005229/en/
Investor and Media Contact: Nick Smith Aptinyx Inc.
ir@aptinyx.com or corporate@aptinyx.com 847-871-0377
Aptinyx (NASDAQ:APTX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Aptinyx (NASDAQ:APTX)
Historical Stock Chart
From Apr 2023 to Apr 2024